NEW YORK - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. This season’s vaccine is indicated as a single dose for most individuals 5 years of age and older. Children under the age of 5 may be eligible to receive additional doses of this season’s vaccine if they have not already completed a three-dose series with previous formulations of a COVID-19 vaccine.

This decision follows guidance from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which recommended an Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for the 2023-2024 fall and winter season. Although Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccines provide some protection against a range of outcomes from XBB-related COVID-19,^2,3 evidence suggests that vaccines better matched to currently circulating strains can offer improved protection against symptomatic and severe disease.⁴ Pfizer and BioNTech have been manufacturing the 2023-2024 COVID-19 vaccine at risk to ensure supply readiness ahead of the fall and winter season, when demand for COVID-19 vaccination is expected to increase in line with the seasonality period also seen with other respiratory viruses.⁵

“This decision comes at a time when COVID-19 cases are once again climbing. Now, most people 6 months or older in the U.S. are eligible to receive this season’s COVID-19 vaccine, even if they have never been vaccinated against COVID-19 before,” said Albert Bourla, Chairman and Chief Executive Officer at Pfizer. “We expect this season’s vaccine to be available in the coming days, pending recommendation from public health authorities, so people can ask their doctor about receiving their COVID-19 vaccine during the same appointment as their annual flu shot, saving time now and helping to prevent severe disease later when respiratory viruses are at their peak.”

“With today's decision, an updated vaccine will shortly become available that helps address multiple Omicron XBB-related sublineages, which currently account for the vast majority of COVID-19 cases globally,” said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Studies about confirmed viral infections suggest that COVID-19 adopts a seasonal pattern with peaks in fall and winter, similar to other respiratory viruses. Our goal is to provide people worldwide with COVID-19 vaccines that are adapted to circulating virus variants or sublineages.”

The approval of this season’s COVID-19 vaccine is based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the COVID-19 vaccines by Pfizer and BioNTech. Further, the application included pre-clinical data showing this season’s vaccine substantially improved responses against multiple Omicron XBB-related sublineages, including XBB.1.5, XBB.1.16, and XBB.2.3, compared to the Omicron BA.4/BA.5-adapted bivalent vaccine. Additionally, pre-clinical data demonstrate that serum antibodies induced by Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, when compared to the Omicron BA.4/BA.5-adapted bivalent vaccine, effectively neutralize the recently emerged Omicron BA.2.86 (Pirola) and the globally dominant Omicron-related EG.5.1 (Eris) subvariant.⁶

This season’s COVID-19 vaccine will be available in pharmacies, hospitals, and clinics across the U.S. following a recommendation by the Centers for Disease Control and Prevention (CDC). The 2023-2024 formulation for individuals 12 years of age and older can be ordered as either a pre-filled syringe or a single-dose vial. The vaccine remains at no out-of-pocket cost to most Americans. For more information, visit www.vaccines.gov.

In the European Union, the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY^® Omicron XBB.1.5) has also received marketing authorization by the European Commission for individuals 6 months of age and older on August 31, 2023. Pfizer and BioNTech have submitted data for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine to other regulatory authorities around the world.

The COVID-19 vaccines (COMIRNATY®) by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines (COMIRNATY Original/Omicron BA.1; COMIRNATY Original/Omicron BA.4/BA.5; COMIRNATY Omicron XBB.1.5) in the United States, the European Union, the United Kingdom and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.

INDICATION, AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION

INDICATION

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine approved for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

IMPORTANT SAFETY INFORMATION

• You should NOT receive COMIRNATY^® (COVID-19 Vaccine, mRNA) if you have had a severe allergic reaction to any ingredient of COMIRNATY or a Pfizer-BioNTech COVID-19 vaccine
• There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination. If you or your pre-teen or teenager experience a severe allergic reaction, call 9-1-1 or go to the nearest hospital. Signs of a severe allergic reaction can include:
  • difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness and weakness
• Authorized or approved mRNA COVID-19 vaccines show increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart), particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age. Seek medical attention right away if you have any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine:
  • chest pain
  • shortness of breath
  • feelings of having a fast-beating, fluttering, or pounding heart
    
    Additional symptoms, particularly in children, may include:
    • Fainting
    • Unusual and persistent fatigue or lack of energy
    • Persistent vomiting
    • Persistent pain in the abdomen
    • Unusual and persistent cool, pale skin
• Fainting can happen after getting injectable vaccines including COMIRNATY. Your vaccination provider may ask you to sit or lie down for 15 minutes after receiving the vaccine
• People with weakened immune systems may have a reduced immune response to COMIRNATY
• COMIRNATY may not protect all vaccine recipients
• Tell your vaccination provider about all of your medical conditions, including if you:
  • have any allergies
  • have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
  • have a fever
  • have a bleeding disorder or are on a blood thinner
  • are immunocompromised or are on a medicine that affects the immune system
  • are pregnant, plan to become pregnant, or are breastfeeding
  • have received another COVID-19 vaccine
  • have ever fainted in association with an injection
• The most commonly reported adverse reactions (≥10%) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), fever (up to 24.3%), joint pain (up to 27.5%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%). These may not be all the possible side effects of the vaccine. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.
  You should always ask your healthcare providers for medical advice about adverse events. Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1‐800‐822‐7967 or report online to www.vaers.hhs.gov/reportevent.html. You can also report side effects to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985

Please click here for full Prescribing Information for COMIRNATY

Please see accompanying full Prescribing Information for COMIRNATY

AUTHORIZED USE

Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)*is FDA authorized under Emergency Use Authorization (EUA) to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.

*Hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine

EMERGENCY USE AUTHORIZATION

Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

IMPORTANT SAFETY INFORMATION

• A person should NOT get Pfizer-BioNTech COVID-19 Vaccine if they had a severe allergic reaction after a previous dose of any Pfizer-BioNTech COVID-19 vaccine or to any ingredients in these vaccines.
• There is a remote chance that the vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, the vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination. If your child experiences a severe allergic reaction, call 9-1-1, or go to the nearest hospital. Signs of a severe allergic reaction can include:
  • difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, or dizziness and weakness
• Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following Pfizer-BioNTech COVID-19 vaccines have occurred most commonly in adolescent males 12 through 17 years of age. In most of these individuals, symptoms began within a few days following vaccination. The chance of having this occur is very low. Seek medical attention right away if your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine:
  • Chest pain
  • Shortness of breath or difficulty breathing
  • Feelings of having a fast-beating, fluttering, or pounding heart

Additional symptoms, particularly in children, may include:

• Fainting
• Unusual and persistent irritability
• Unusual and persistent poor feeding
• Unusual and persistent fatigue or lack of energy
• Persistent vomiting
• Persistent pain in the abdomen
• Unusual and persistent cool, pale skin
• Fainting can happen after getting injectable vaccines, including Pfizer-BioNTech COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination
• People with weakened immune systems may have a reduced immune response to Pfizer-BioNTech COVID-19 Vaccine
• The Pfizer-BioNTech COVID-19 Vaccine may not protect everyone
• Tell your vaccination provider about all of your medical conditions, including if you:
  • have any allergies
  • has had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)
  • has a fever
  • has a bleeding disorder or are on a blood thinner
  • is immunocompromised or are on a medicine that affects the immune system
  • is pregnant or is breastfeeding
  • has received another COVID-19 vaccine
  • has ever fainted in association with an injection
• Side effects that have been reported with Pfizer-BioNTech COVID-19 vaccines include:
  • Severe allergic reactions
  • Non-severe allergic reactions such as rash, itching, hives, or swelling of the face
  • Myocarditis (inflammation of the heart muscle)
  • Pericarditis (inflammation of the lining outside the heart)
  • Injection site pain/tenderness
  • Tiredness
  • Headache
  • Muscle pain
  • Arm pain
  • Fainting in association with injection of the vaccine
  • Chills
  • Joint pain
  • Fever
  • Injection site swelling
  • Injection site redness
  • Nausea
  • Feeling unwell
  • Swollen lymph nodes (lymphadenopathy)
  • Decreased appetite
  • Diarrhea
  • Vomiting
  • Dizziness
  • Irritability

These may not be all the possible side effects. Serious and unexpected side effects may occur. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.

OAKLAND, CA – In partnership with six district attorneys, California Attorney General Rob Bonta today announced a settlement with Kaiser Foundation Health Plan, Inc., and Kaiser Foundation Hospitals (collectively “Kaiser”) resolving allegations that the healthcare provider unlawfully disposed of hazardous waste, medical waste, and protected health information at Kaiser facilities statewide. As part of the settlement, Kaiser will be liable for a total of $49 million and be required to take significant steps to prevent future unlawful disposals.

“The illegal disposal of hazardous and medical waste puts the environment, workers, and the public at risk. It also violates numerous federal and state laws,” said Attorney General Rob Bonta. “As a healthcare provider, Kaiser should know that it has specific legal obligations to properly dispose of medical waste and safeguard patients’ medical information. I am pleased that Kaiser has been cooperative with my office and the district attorneys’ offices, and that it took immediate action to address the alleged violations.”

The settlement is the result of undercover inspections conducted by the district attorneys' offices of dumpsters from 16 different Kaiser facilities. During those inspections, the district attorneys' offices reviewed the contents of unsecured dumpsters destined for disposal at publicly accessible landfills, finding hundreds of items of hazardous and medical waste (aerosols, cleansers, sanitizers, batteries, electronic wastes, syringes, medical tubing with body fluids, and pharmaceuticals) and over 10,000 paper records containing the information of over 7,700 patients. The California Department of Justice subsequently joined the district attorneys and expanded the investigation of Kaiser’s disposal practices further throughout the state. In response to this joint law enforcement investigation, Kaiser immediately hired a third-party consultant and conducted over 1,100 trash audits at its facilities in an effort to improve compliance. Kaiser also modified its operating procedures to improve its handling, storage, and disposal of waste.    

Kaiser is headquartered in Oakland, California and operates over 700 facilities statewide, making it the largest healthcare provider in California. Kaiser provides healthcare to approximately 8.8 million Californians, as well as members of the public who seek emergency care from Kaiser facilities. In announcing today’s settlement, Attorney General Bonta is joined by the district attorneys of Alameda, San Bernardino, San Francisco, San Joaquin, San Mateo, and Yolo counties.

“As a major corporation in Alameda County, Kaiser Permanente has a special obligation to treat its communities with the same bedside manner as its patients,” said Alameda County District Attorney Pamela Price. “Dumping medical waste and private information are wrong, which they have acknowledged. This action will hold them accountable in such a way that we hope means it doesn’t happen again.”

“I am confident that this case shows the residents of San Bernardino County that our Office will not stand by as hospitals and other medical clinics dispose of medical waste including biohazards, hazardous waste and personal health information into our landfills, jeopardizing medical confidentiality,” said San Bernardino County District Attorney Jason Anderson. “Deputy District Attorney’s Stephanie Weissman and Supervising Deputy District Attorney Doug Poston dedicated years of their time and expertise to ensure the residents of our County are protected from the mishandling of medical waste and Kaiser policies are improved to safeguard the public moving forward."

“My office takes patient privacy and the protection of the environment very seriously,” said San Francisco District Attorney Brooke Jenkins. “Hazardous waste, medical waste, and confidential patient information must be disposed of properly. When it is not, we will not hesitate to take action. Protecting patient privacy and the environment is just as important as protecting public safety.”

“This resolution further protects the health and safety of the residents of San Joaquin County and the state as a whole,” said San Joaquin County District Attorney Ron Freitas. “The unlawful disposal of hazardous medical waste has no place in this county, or any county, and the mishandling of confidential patient information will not be tolerated. The settlement with Kaiser places the appropriate safeguards to ensure that this never happens again.”

“As the largest healthcare provider in the state, Kaiser has an extraordinary responsibility to the public and to its own patients to ensure that hazardous waste, potentially infectious human waste materials, and highly sensitive patient health information are handled according to state laws and not sent to municipal landfills not equipped to handle those wastes,” said San Mateo County District Attorney Stephen M. Wagstaffe. “Our Environmental Unit continues to work with San Mateo County environmental regulators and colleagues across the state to investigate and prosecute entities that break the law and endanger the environment.”

As part of the settlement, Kaiser:

• Will pay $47.250 million. That amount includes $37,513,000 in civil penalties; $4,832,000 in attorneys’ fees and costs; and $4,905,000 for supplemental environmental projects, primarily environmental prosecutor training.
• Must pay an additional $1.75 million in civil penalties if, within 5 years of the entry of the final judgment, Kaiser has not spent $3.5 million at its California facilities to implement enhanced environmental compliance measures to ensure compliance with relevant provisions of the law that are alleged to have been violated.
• Must retain an independent third-party auditor — approved by the Attorney General’s Office and the district attorneys — who will: perform no less than 520 trash compactor audits at Kaiser’s California facilities to help ensure that regulated wastes (including items containing protected health information) are not unlawfully disposed of; and conduct at least 40 programmatic field audits each year, for a period of five years after entry of the final judgment, to evaluate Kaiser’s compliance with policies and procedures designed to ensure compliance with applicable laws related to hazardous waste, medical waste, and protected health information.

Kaiser’s unlawful disposals are alleged to violate California’s Hazardous Waste Control Law, Medical Waste Management Act, Confidentiality of Medical Information Act, Customer Records Law, and Unfair Competition Law. The disposals are also alleged to violate the federal Health Insurance Portability and Accountability Act of 1996, known as HIPAA.

In 2014, the California Department of Justice filed a lawsuit against Kaiser after it delayed notifying its employees about an unencrypted USB drive that was discovered at a Santa Cruz thrift store. The USB drive contained over 20,000 employee records. Kaiser paid $150,000 in penalties and attorneys' fees, and agreed to comply with California's data breach notification law in the future, provide notification of any future breach on a rolling basis, and implement additional training regarding the sensitive nature of employee records. In addition, Kaiser has been the subject of prior enforcement actions by local prosecutors for mismanagement of regulated wastes.

A copy of the complaint and proposed stipulated judgment, which details the aforementioned settlement terms and remains subject to court approval, can be found here and here.

LEBANON, TN – Health Connect Partners, a leading organization for bringing hospital providers and suppliers together through industry-specific conferences, launched Pharmacy Angle, a new website, e-newsletter and social media channels (LinkedIn, Twitter, Facebook and Instagram) to serve as a comprehensive digital resource for hospital pharmacy professionals. 

This new media platform will serve as a central hub for hospital pharmacy professionals looking for industry news and trending topics, the sharing of information and best practices through written word and video from their peers and thought leaders, and for connecting buyers with suppliers through a comprehensive Supplier Directory. 

TAMPA, FL - Drug shortages are a significant crisis for our nation's patients, hospitals, physicians, and pharmacists. 99% of hospital pharmacists are navigating at least one essential medicine shortage every day. Patients and prescribers across the United States must have equal access to the medicines they need to survive.  

In 2022, Angels for Change launched Project PROTECT, a new approach to mitigate drug shortages by building redundant onshore supply of vulnerable essential medicines. Utilizing drug shortage prediction powered by USP’s Medicine Supply Map, supply chain partnerships, and non-profit grants that incentivize production, we proactively predicted two shortages and increased supply, thus limiting patient impact of the disruption. This work resulted in 700,000 life-saving drug shortage treatments accessed by patients, mostly children, across the United States. Read more here.   

Today, Angels for Change announces our 2023 Project PROTECT grant award winners and the seven essential medicines they will take on as Protectors. Each PROTECT grant was funded through grass roots, charitable fundraising activities and presented to representatives of PROTECT organizations in-person by Founder and Chief Change Maker, Laura Bray.   

Fagron, a global leader in pharmaceutical compounding, was awarded a Project PROTECT grant on May 17, 2023, for the essential medication Dextrose. Fagron Sterile Services US (FSS), a leading FDA-registered and inspected 503B Outsourcing partner to hospitals, clinics, and ambulatory surgery centers in all 50 states, will produce this essential medication. FSS produces sterile medications at state-of-the-art facilities located in Boston, MA, and Wichita, KS.  

FSS has a long history of supporting patient care through its work with IDNs and GPOs to create supply chain resiliency while advancing patient safety. With the Angels for Change grant, FSS will develop and produce Dextrose so that patients across the US will continue to have access to this at-risk medication. Dextrose is widely used for critical IV solutions and nutritional support.

"We are honored to be recognized as a Protector of Dextrose by Angels for Change," said Andrew Pulido, President, Fagron North America. "Our global footprint and our team's unwavering dedication to maintaining a robust supply chain help ensure that patients receive the vital medication they need – without disruption. This partnership serves as a testament to our ongoing commitment to patients and excellence in pharmaceutical compounding."

On June 28, 2023, Leiters Health was awarded 4 project PROTECT grants for Magnesium, Calcium Chloride, Potassium Acetate and Sodium Phosphate. Leiters provides high-quality compounded sterile preparations across the healthcare continuum to hospitals, surgery centers, clinics and physician offices. As part of its ongoing commitment to quality, compliance, and sterile manufacturing excellence, Leiters continues to invest in its state-of-the-art FDA-registered 503B facilities, including two existing facilities in Denver, Colorado, and a new facility in Buena, New Jersey, which will be operational in 2024.  

“Drug shortages are a concerning public health issue. They cause major disruption to the healthcare supply chain, pharmacy operations, and ultimately negatively impact patient care," said Joseph Cosgrove, President, and Chief Executive Officer of Leiters Health. “We look forward to working with Angels for Change and we stand ready to support the critical medication needs of the healthcare community now and in the future.”

STAQ Pharma, a 503B Outsourcing Facility with locations in Denver, CO and Columbus, OH was awarded two project PROTECT grants on June 29, 2023 for Furosemide and Bumetanide. STAQ was also awarded 2 grants in 2022 for Potassium Chloride and Sodium Chloride becoming the Protector of 4 essential medicines. STAQ Pharma is known in the industry as the "Hospital Owned 503B'' because of its equity ownership by hospitals, its commitment to quality, its ability to produce long dated compounded products under cGMP, the on-going membership on its Board of Directors of Hospital Executives, and because of its work focusing on drug shortages experienced regularly by adult pediatric hospitals. Furosemide and Bumetanide are used to reduce extra fluid in the body (edema) caused by conditions such as congestive heart failure, liver disease, and kidney disease. There are limited alternatives to these drugs. Protecting them together will ensure consistent supply across the country in a ready to administer format.

“STAQ Pharma is proud to support Angels for Change and our partner hospitals through the PROTECT program. We have seen firsthand how this program has been able to support over 700,000 patients with lifesaving medications and are excited to continue into the next phase with additional medications where we can support millions of patients,” said President Mark Spiecker.   

“Last year, we took the step to protect patients from shortage of just two medicines and that step resulted in 700,000 treatments being accessed. 700,000 times lives were saved! I am thankful that Fagron, Leiters, and STAQ Pharma were willing to become Protectors with us as we scale this project and proud that by the end of 2023, we will have protected patients from the impact of shortage for 9 essential medicines.” said Laura Bray.  

Project PROTECT is a scalable model developed to protect US patients from the impact of more than 100 essential medicines vulnerable to shortage. Angels for Change is committed to continue to partner with the supply chain to protect these life-saving medicines ensuring access for all patients. To learn more about PROTECT go to https://www.angelsforchange.org/project-protect 

BRIDGEWATER, NJ - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is currently on the U.S. FDA shortage product list.

The product approval received the FDA’s Competitive Generic Therapy (“CGT”) designation with 180-day exclusivity. Amneal has the highest number of CGT approvals in the U.S. Generics industry.

Calcium gluconate in sodium chloride injection is a small volume parenteral bag indicated for the treatment of acute symptomatic hypocalcemia in pediatric and adult patients. Key Warning: Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger.) For full prescribing information, see package insert located here.

“The approval of calcium gluconate injection, a key injectable in shortage, reflects our commitment to addressing immediate patient needs for essential medicines. This is part of our concerted strategy to address long-term shortages in the market. We look to partner with our customers to deliver these essential medicines to providers who need them and the patients they serve,” said Harsher Singh, Senior Vice President, Amneal Biosciences.

According to IQVIA®, U.S. annual sales for calcium gluconate in sodium chloride injection for the 12 months ended June 2023 were $107 million.

ROLLING MEADOWS, IL - In 2023, 9 in 10 employers (90%) increased their support for one or more core employee wellbeing dimensions, including physical, emotional, career and financial. As a result, total rewards investments made in 2023 are likely to be based on their potential to create stronger organizational attachment, according to Gallagher's 2023 US Physical & Emotional Wellbeing Report. The Gallagher report examined how employers are adjusting to top trends in employee physical and emotional wellbeing and using these trends to help improve employees' quality of life at and outside of work.

"Today's workforces consist of multiple generations and people from a variety of backgrounds, and this requires employers to analyze whether their benefit offerings are addressing a wide range of employee needs," said William F. Ziebell, CEO of Gallagher's Benefits & HR Consulting Division. "As organizations continue to focus on recruiting and retention as top operational and HR priorities, it's clear that they're paying closer attention to important issues, such as flexibility, burnout and inclusive medical coverage."

The Gallagher study, which is the second installment of the 2023 US Workforce Trends Report Series, was conducted from December 2022 to March 2023 and sourced data and insights from more than 4,000 organizations across the US. The study presents recent findings on current and emerging trends to help employers optimize their investments in employee physical and emotional wellbeing by covering medical, pharmacy and voluntary benefits, as well as absence management strategies.

Pervasive concerns about stress and burnout spark continued focus on emotional wellbeing.

The focus on emotional wellbeing in the workplace continues its upward trend with more than 7 in 10 employers (74%) increasing the importance of this area in 2023. While prioritization of wellbeing starts at the top, more meaningful interactions take place at the operational level. In fact, since last year, providing mental health training for managers, leaders or HR increased by 5 points to 22%.

Employers are investing in building morale, addressing these concerns through clinical care and designated time off for mental health. Roughly 7 in 10 employers (71%) offer clinical care such as virtual or telephonic mental health counseling, and 25% are allowing time off for mental health and burnout (up from 3 points in 2022).

Employers are updating PTO and leave policies that account for life outside of work.

Nearly all employers (96%) offer paid time off (PTO) to full-time employees, and more than 4 in 5 (81%) allow employees to carry over days into future years. The ability to help employees meet their work-life integration needs relies on flexible PTO policies. But less than half (47%) include separate vacation, sick or personal days and only 5% offer unlimited PTO.

The future of absence management is evolving as employers accommodate an aging workforce, mental health challenges and changing benefit expectations. As such, employers have developed strategies for administering leaves and disabilities (49%) or expect to do so in the next two years (15%).

Employers are increasingly adapting to align paid leaves with family-focused policies. For example, access to new child or parent bonding paid leave has increased 5 points from 2022 to 41%. And while just 13% of employers offer paid caregiver leave, of those who offer caregiver leave, the majority provide 11–12 weeks (40%).

Balancing demands for specialty drugs and treatments with rising healthcare plan premiums.

Median health plan premium increases at the most recent renewal were 5%–5.9%, up from 4%–4.9% in 2022, and nearly 4 in 5 employers (78%) believe a moderate or significant rise in healthcare costs is likely this year. Nevertheless, nearly 2 in 5 employers (39%) enhanced their medical benefits in 2023, up 6 points from 2022. After base salary and variable compensation, medical benefits received the most attention from employers (39%), up 6 points from 2022. As a result, the use of employee cost sharing and other cost-management tactics is likely to grow.

Coverage for infertility, autism or transgender services and other specialty treatments can show support for ranging employee populations. Though most of these benefits don't stabilize or lower costs, they often align with preferences that strengthen cultural inclusivity. However, their availability was uneven — autism (53%) and fertility services (46%) are offered by nearly half of employers, voluntary pregnancy termination by one-third (34%) and gender reassignment surgery by one-quarter (25%).

Challenges remain in managing specialty drugs (e.g., weight loss, gene therapies, biosimilars), and 48% of employers don't know or don't use tactics to manage their use and costs. Given the accelerating interest in weight loss drugs specifically, and the high costs associated, employers could quickly absorb expenses that exceed their budget limit and impose other strains on their pharmacy benefit plans.

"It is essential to recruitment, retention and the overall wellbeing of employees to serve diverse needs," said Ziebell. "As such, employers should determine what approaches to coverage and utilization will provide the best results for their employee populations, without driving excessive costs."

FDA is announcing two compliance policy guidances establishing a 1-year stabilization period to accommodate additional time that trading partners in the pharmaceutical supply chain may need to adhere to Drug Supply Chain Security Act (DSCSA) requirements for electronic drug tracing at the package level.

Under the DSCSA, trading partners – primarily manufacturers, wholesale distributors, dispensers, and repackagers – are subject to certain requirements for enhanced drug distribution security.

The DSCSA, enacted in 2013, outlines steps to achieve interoperable, electronic tracing of products to identify and trace certain prescription drugs as they are distributed throughout the U.S. The DSCSA requires trading partners to provide, receive and maintain documentation about prescription drugs and their chain of ownership from manufacturer to dispenser as the drugs are distributed in the U.S. supply chain. Currently, these entities can choose to provide such information either electronically or in paper format.

Those DSCSA requirements are scheduled to change on November 27, 2023, and will include requiring trading partners to provide, receive and maintain documentation about products and ownership only electronically. The stabilization period will accommodate an additional year, until November 27, 2024, to allow trading partners to implement, troubleshoot and mature their electronic interoperable systems. The stabilization period is intended to avoid disruption to the supply chain and ensure continued patient access to drug products as trading partners work to fully implement the enhanced drug security requirements.

“FDA is committed to successful implementation of interoperable systems required under the DSCSA,” said Leigh Verbois, director of CDER’s Office of Drug Security, Integrity and Response. “We have heard concerns about supply chain readiness, and we believe that some flexibility will support successful implementation and lead to a stronger and safer drug supply chain.”

As explained in the guidance, FDA does not intend to enforce the enhanced drug distribution security requirements under section 582(g)(1) of the the Federal Food, Drug, and Cosmetic (FD&C) Act during this stabilization period to help trading partners transition to full implementation. Additionally, FDA does not intend to enforce section 582(g)(1)(B) of the FD&C Act with respect to drug product that is introduced in a transaction into commerce by the product’s manufacturer or repackager before November 27, 2024, and for subsequent transactions of such product through the product’s expiry.

FDA expects trading partners to use this stabilization period to build and validate interoperable systems and processes, manage products and data, and ensure continuity of the supply chain and product availability to patients. This period is not intended to provide, and should not be viewed as providing, a justification for delaying efforts to comply with the DSCSA.

The compliance policies support trading partners’ use of current methods to exchange and store documentation about products and their chain of ownership, investigate and report suspect or illegitimate product, and handle saleable returns.

The two guidances FDA issued are:

• an immediately-in-effect compliance policy guidance, Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act – Compliance Policies. This guidance describes FDA’s compliance policies regarding enforcement of requirements for enhanced drug distribution security requirements under section 582(g)(1) of the FD&C Act.
• a revised final compliance policy guidance, Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product  —Compliance Policies. This guidance describes FDA’s compliance policies regarding enforcement of requirements for wholesale distributors and dispensers to verify a product’s product identifier in certain circumstances under sections 582(c)(4) and 582(d)(4) of the FD&C Act.

STOUGHTON, MS & CHATTANOOGA, TN - Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, announced today that it has partnered with Tennessee-based Erlanger to establish a new specialty pharmacy program. The collaboration with the nationally-acclaimed, multi-hospital health system will provide patients who have complex, chronic conditions increased access to specialized pharmacy services developed to lower costs, bolster treatment options, improve medication management, and enhance overall health.

The partnership will initially serve three disease states: neurology, rheumatology, and gastroenterology, with the intent to expand to additional patient populations. With the new partnership, specialty pharmacy liaisons will guide patients and caregivers who fill prescriptions with Erlanger, working with patients on-site. Among other tasks, these liaisons can assist patients and families with navigating barriers to care including health insurance, prior authorizations, or securing financial assistance.

Expanded patient support services in conjunction with access to recently approved and newly available specialty medications, will offer Erlanger patients greater availability for on-site treatment options. Shields currently partners with nearly 80 health systems around the country and has helped their patients reduce co-pays, promptly receive medication delivery — often within two days — and improved medication adherence greater than 90 percent on average.

“The newly formed specialty pharmacy at Erlanger marks a commitment to expanding the reach of the health system’s services and providing superior patient care in the Chattanooga area,” said John Lucey, CEO at Shields. “Our partnership will increase access to affordable care and improve therapy management and care coordination for Erlanger’s patients. Shields leverages our access to 90 percent of the limited distribution drugs to provide complex patients with the therapy they need and help them navigate restricted payer networks.”

The region’s only academic teaching hospital, Erlanger serves a broad patient population across portions of Tennessee, Georgia, North Carolina, and Alabama. It is the tri-state region’s only Level I Trauma Center and treats more than a million patients annually. Erlanger is comprised of seven total hospitals, including one pediatric facility, a behavioral health hospital, and a stroke center that has received recognition for its exhaustive stroke and neurosciences program.

“Our partnership with Shields and the new specialty pharmacy program will permit us to enhance the premium care we provide to our communities,” said Rob Maloney, COO at Erlanger. “We are delighted to join Shields’ network of premier health systems and leverage insights and experience from the foremost experts in the health system specialty pharmacy industry.”

Advance Market Analytics published a new research publication on "Pharmacy Automation Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Pharmacy Automation market was mainly driven by the increasing R&D spending across the world.

Some of the key players profiled in the study are:
Becton, Dickinson, and Company (United States), Omnicell, Inc. (United States), Cerner Corporation (United States), Capsa Healthcare (United States), Parata Systems LLC (United States), Baxter International, Inc. (United States), ScriptPro LLC (United States), KUKA AG (Germany), TCGRx Pharmacy Workflow Solutions (United States), RxSafe, LLC (United States), ARxIUM Inc. (United States), Talyst Systems, LLC (United States).

Scope of the Report of Pharmacy Automation
Pharmacy automation refers to the integration of advanced technologies and automated systems within a pharmacy environment to streamline and enhance various aspects of medication management, dispensing, and patient care. This innovative approach aims to optimize workflow efficiency, improve medication accuracy, reduce human errors, and ensure the safe and timely delivery of pharmaceutical products and services. Pharmacy automation encompasses a range of solutions that span from robotic dispensing systems to electronic health record (EHR) integration. Key components of pharmacy automation include robotic prescription dispensing systems, which accurately count, package, and label medications, minimizing the risk of errors and ensuring precise dosing. Automated medication storage and retrieval systems enable efficient inventory management and quick access to the required medications, improving the speed of dispensing and reducing wait times for patients.

The titled segments and sub-section of the market are illuminated below:
by Type (Automated Medication Dispensing Systems, Automated Packaging and Labeling Systems, Automated Storage and Retrieval Systems, Automated Medication Compounding Systems, Table Top Tablet Counters), End User (Inpatient Setting, Acute-Care, Long-Term Care, Outpatient Setting, Retail Pharmacy Chains, Outpatient/Fast-Track Care, Hospital Retail, Pharmacy Benefit Management Services, Other (Mail-Order Settings))

Market Drivers:
Rising Geriatric Population
Growing Need to Minimize Medication Errors
Rapid Decentralization of Pharmacies

Market Trends:
Upsurging Demand and Consumption has Led to Continues Enhancements in the Industry

Opportunities:
Healthcare Cost-reduction Measures
Increasing Awareness Among Pharmacists
Emerging Markets

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Strategic Points Covered in Table of Content of Global Pharmacy Automation Market:

• Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Pharmacy Automation market
• Chapter 2: Exclusive Summary - the basic information of the Pharmacy Automation Market
• Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Pharmacy Automation
• Chapter 4: Presenting the Pharmacy Automation Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
• Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020
• Chapter 6: Evaluating the leading manufacturers of the Pharmacy Automation market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
• Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2027)
• Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source
  
  Finally, Pharmacy Automation Market is a valuable source of guidance for individuals and companies.
  
  Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/69554-global-pharmacy-automation-market-1#utm_source=OpenPR/Suraj 

Brewton, AL – D.W. McMillan Memorial Hospital announced that Amy Holland has been selected as the Pharmacy Director. In her new position, she will be responsible for the overall operations of the hospital pharmacy dispensing functions for inpatient and outpatient medications. She will assume the role previously held by Phillip Parker.

“Amy is an outstanding leader and we are excited to have her step into this leadership role.” stated Stacy Hines, Hospital Administrator. “We are very thankful to Mr. Parker for over 44 years of dedication to D.W. McMillan Memorial Hospital where he has served as pharmacist and administrator,” stated Hines. “We are happy to have him remain on staff as a pharmacist as part of this transition.”

Prior to joining D.W. McMillan Memorial Hospital, Amy has worked as a pharmacy tech and as a pharmacist in Monroeville, Opelika, and Brewton. She has also worked for various health related entities such as Monroe County Hospital, Winn Dixie Pharmacy, Rite Aid, Wal-Mart and Monroe Drugs.

Amy earned her Doctorate of Pharmacy (PharmD) in 2011 from Auburn University’s Harrison School of Pharmacy. She is also a graduate of Monroe Academy. Amy lives in Castleberry with her husband, Randy and their two children.